CommercialCoverageHigh impact
Paralytic Lagophthalmos Treatments (CPB 0366, reviewed 2026-05-22)
Aetna·Ophthalmology, Plastic Surgery, Neurosurgery +1 more·Medical Policy
Effective date
May 22, 2026
We identified it
Aug 13, 2026
Summary
Aetna has updated Clinical Policy Bulletin 0366 (reviewed 2026-05-22) establishing clear medical necessity criteria for paralytic lagophthalmos treatments. Gold-weight/platinum-weight eyelid implants and palpebral springs are now covered only when specific selection criteria are met (delayed facial nerve recovery, exposed cornea, failed conservative treatment). Multiple procedures including muscle transposition, neuroplastic surgery, and autologous spacing grafts are covered for chronic severe cases with no spontaneous recovery likelihood. Botulinum toxin, cerclage sling, hyaluronic acid, and lipofilling remain experimental/unproven. Billing teams must immediately implement prior authorization requirements and ensure correct coding per the expanded covered procedure list.
Action Required
By 2026-05-22: Billing team must immediately implement the following changes: (1) Update billing system to require prior authorization for all paralytic lagophthalmos treatment CPT codes (15760, 64864, 64865, 64885, 64886, 67320, 67912) when billed with ICD-10 codes H02.231-H02.239 (paralytic lagophthalmos). (2) Create pre-authorization checklist requiring documentation of: delayed facial nerve recovery prognosis, presence of exposed cornea with inadequate lacrimation, and failure of conservative treatment (lubricants, moisture chambers, taping). (3) Deny or route to medical review all claims for CPT 15773, 15774, 21282, 64612, and J0585 when billed for paralytic lagophthalmos indications—these are non-covered experimental procedures per policy. (4) Update encounter templates and provider education materials to highlight selection criteria. (5) Train front-desk and authorization staff on the three required conditions for gold-weight/platinum-weight/palpebral spring implant approval. Failure to obtain prior authorization or improper coding of experimental procedures will result in claim denials.